Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size

References

• Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317–26
   PubMed Web of Science ®Google Scholar
• Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharmaceut Sci 1998;1:15–30
   PubMedGoogle Scholar
• Mathiowitz E, Chickering DE, Lehr C-M. Bioadhesive drug delivery systems: fundamentals, novel approaches and development. New York: Marcel Dekker
   Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 1999;56:588–99
   Google Scholar
• Alexander A, Dwivedi S, Ajazuddin, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Rel 2012;164:26–40
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats. Drug Dev Ind Pharm 2012. [Epub ahead of print]. doi:10.3109/03639045.2012.738684
   Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Subcutaneous administration of nano- and microsuspenions to rats. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi:10.3109/03639045.2013.771645
   Web of Science ®Google Scholar
• Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63:901–8
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Björkman J-A, Skantze P, Zachrisson H. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound. J Pharm Sci 2011;100:2194–202
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59:603–16
   PubMed Web of Science ®Google Scholar
• Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2013;453:142--56
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309–13
   Web of Science ®Google Scholar
• Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16
   PubMed Web of Science ®Google Scholar
• Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald Ripening. Langmuir 2006;22:906–10
   Google Scholar
• Sigfridsson K, Forssen S, Holländer P, et al. A formulation comparison, using solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm 2007;67:540–7
   PubMed Web of Science ®Google Scholar
• Müller RH, Böhm BHL. Nanosuspensions In: Muller RH, Benita S, Böhm BHL, eds. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publishers; 1998:149–74
   Google Scholar
• Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004;284:109–22
   PubMed Web of Science ®Google Scholar
• Mersiko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427–40
   PubMed Web of Science ®Google Scholar
• Scala-Bertola J, Javot L, Camargo JA, et al. Evaluation of subcutaneous forms in the improvement of pharmacokinetic profile of warfarin. Int J Pharm 2012;431:33–8
   PubMedGoogle Scholar
• IUPAC. Compendium of chemical terminology. 2nd ed. (the “Gold Book”). Compiled by McNaught AD, Wilkinson A. Oxford: Blackwell Scientific Publications; 1997. doi:10.1351/goldbook.O04348
   Google Scholar
• Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• van Eerdenbrugh B, van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008;364:64–75
   PubMed Web of Science ®Google Scholar
• Bosselmann S, Williams III RO. Has nanotechnology led to improved therapeutic outcomes? Drug Dev Ind Pharm 2012;38:158–70
   PubMed Web of Science ®Google Scholar
• Barenholz Y, Amselen S, Goren D, et al. Stability of liposomal doxorubicin formulations: problems and prospects. Med Res Rev 1993;13:449–91
   PubMed Web of Science ®Google Scholar
• Pandit N, Trygstad T, Croy S, et al. Behavior of pluronic 127 solutions. J Colloid Interface Sci 2000;222:213–20
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV, Mun GA, Nurkeeva ZS, Dubolazov AV. pH and salt effects on interpolymer complexation via hydrogen bonding in aqueous solutions. Polym Int 2004;53:1382–7
   Web of Science ®Google Scholar
• Overhoff KA, McConville IT, Yang W, et al. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res 2008;25:167–75
   PubMed Web of Science ®Google Scholar
• Comba S, Sethi R. Stabilization of highly concentrated suspensions of iron nanoparticles using shear-thinning gels of xanthan gum. Water Res 2009;43:3737–26
   Google Scholar
• Tanaka Y, Inkyo M, Yumoto R, et al. Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption. Drug Dev Ind Pharm 2012;38:1015–23
   PubMed Web of Science ®Google Scholar
• Heinemann L. Variability of insulin action: does it matter? Insulin 2008;3:37–45
   Google Scholar
• Söeberg T, Rasmussen CH, Mosekilde E, Colding-Jörgensen M. Bioavailability and variability of biphasic insulin mixtures. Eu J Pharm Sci 2012;46:198–208
   PubMed Web of Science ®Google Scholar
• Brunfeldt K, Poulsen, J. Protamine-splitting enzyme from serum and subcutaneous tissue. Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium, vol. 5; 1953:51–61
   Google Scholar
• Berger M, Halban P, Girardier L, et al. Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia 1979;17:97–9
   PubMed Web of Science ®Google Scholar
• Paulsen P, Courtney III J, Duckworth W. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 1979;28:640–5
   PubMed Web of Science ®Google Scholar
• Deckert T. Subcutaneous degradation of insulin. Diabetologia 1981;21:161–2
   PubMed Web of Science ®Google Scholar
• Porter C, Charman S. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000;89:297–310
   PubMed Web of Science ®Google Scholar
• Noyes A, Whitney W. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897;19:930–4
   Google Scholar
• Subramaniam B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 1997;86:885–90
   PubMed Web of Science ®Google Scholar
• Gupta RB, Kompella UB, eds. Nanoparticle technology for drug delivery. New York: Taylor & Francis; 2006
   Google Scholar
• Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008;3:295–309
   PubMed Web of Science ®Google Scholar
• Bisrat M, Nyström C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 1988;47:223–31
   Google Scholar
• Mosharraf M, Nyström C. The effect of particle-size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm 1995;122:35–47
   Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor – the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm 2011;37:1036–42
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen CB, Guo LS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1993;1150:9–16
   PubMed Web of Science ®Google Scholar
• Ullmansky R, Turjeman K, Baru M, et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Controlled Release 2012;160:299–305
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm 2011;37:185–92
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm 2011;37:243–51
   PubMed Web of Science ®Google Scholar